Balanced View on Phreesia: Solid Profitability Gains Offset by Weaker Growth Visibility and Elevated Execution Risk Supporting a Hold Rating

In a report released yesterday, Alexei Gogolev from J.P. Morgan maintained a Hold rating on Phreesia, with a price target of $16.00.

Alexei Gogolev has given his Hold rating due to a combination of factors, balancing Phreesia’s solid execution with rising uncertainties in its outlook. He acknowledges the company’s improving profitability, including positive GAAP earnings, strong free cash flow, and a clear focus on margin expansion supported by initiatives in payments, provider marketing, and AI-driven efficiencies.

At the same time, he views the roughly 7% cut to FY27 revenue guidance, slower growth in network solutions, and reduced expectations for revenue per client as signals of weaker growth visibility and heightened execution risk. These issues are compounded by increased dependence on pharma marketing budgets, which are subject to brand-specific swings and limited line-of-sight, leading him to see better risk‑reward opportunities elsewhere in HealthTech despite Phreesia’s long‑term potential and discounted valuation.

In another report released today, Robert W. Baird also downgraded the stock to a Hold with a $10.00 price target.